韩 霞,陈 浩,顾 煜

度普利尤单抗是一种全人源白细胞介素（interleukin，IL）⁃4受体α亚基的单克隆抗体，可有效阻断Th2型炎症反应的发生。在欧美国家及我国,目前度普利尤单抗适用人群已推广至6岁以下患儿[1-2]，随着度普利尤单抗治疗特应性皮炎应用的增多,药物的一些副作用逐渐被报道，常见副作用包括注射局部反应、眼部疾患、头颈部红斑､银屑病等[3]，引起皮肤色素脱失的白癜风样改变报道较少。本文报道一例应用度普利尤单抗治疗特应性皮炎12个月后，双侧耳前皮肤出现白癜风样改变的案例。

度普利尤单抗；特应性皮炎；白癜风样改变

[1] Xiao Chuanliu;Lin Hongchang;Luo Yang;Cui Lixia;Epidemiological Investigation of Atopic Dermatitis in Preschool Children in Haikou[J].Practical Preventive Medicine,2021(12):69-72. [2] Luo Ruijing;Liu Jie;Peng Yong;Wang Yingjie;Jiang Zhuqian;Wu Zongqin;Li Shu;Chai Weihan;Huang Pinxian;he Jiancheng;Clinical epidemiological investigation on distribution of TCM syndromes in children with atopic dermatitis in Jiading district of Shanghai[J]. Chinese Journal of Dermatology and Venereology,2019(08):89-94. [3] Zhang Peilian and Ye Jianzhou,January 2024,Volume 38,Phase 1,Adverse Reactions and Prevention and Treatment of Dupleurumumab in the Treatment of Atopic Dermatitis. [4] Huang Xin;Chen Xiaoyun;Li Yaping;Liang Xingkun;Zhang Guiying;Zhou Ying;Zhan Yi;Luo Shuaihan Tian;Liao Jieyue;Xiao Rong;Longhai,J.Efficacy and safety analysis of dupriumumab in the treatment of 123 patients with atopic dermatitis[J].Chinese Journal of Dermatology,2022(06). [5] Frisoli ML,Essien K,Harris JE.Vitiligo:Mechanisms of pathogene⁃sis and treatment[J].Annu Rev Immunol,2020,38:621⁃648. [6] Sushama S,Dixit N,Gautam RK,et al.Cytokine profile(IL-2,IL-6,IL-17,IL-22,and TNF⁃α)in vitiligo⁃New insight into path⁃ogenesis of disease[J].J Cosmet Dermatol,2019,18:337-341. [7] 温广东,冒丹丹,张原媛,等.度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J].中华皮肤科杂志,2022,55(6):508-510. [8] 赵蓉蓉,亓玉青,范丽云,等.度普利尤单抗治疗重度痒疹型特应性皮炎2例[J].中华皮肤科杂志,2022,55(4):339-341. [9] 边赛男,崔乐,关凯.应用度普利尤单抗治疗后出现皮肤白癜风样改变一例报告及文献复习[J].中华临床免疫和变态反应杂志, 2024,18(03):293-295. [10] 李萌萌,黎静宜,刘青锋,刘友庆,李薇.度普利尤单抗治疗中重度特应性皮炎16周疗效和安全性分析[J].中国麻风皮肤病杂志, 2022,38(12):849-852.

点击下载PDF